ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In order to assess whether miR-29a-3p up-regulation observed in CML LSCs is involved in the escape from TKIs treatment, miR-29a-3p was overexpressed in K562 cells and its effects on BCR-ABL kinase activity and cell survival in presence of TKIs treatment (1 μM IM for 24 h or 0.4 μM IM for 48 h, or 10 nM Ponatinib for 24 h, or 100 nM Dasatinib for 24 h) were evaluated.